» Articles » PMID: 22406973

A Transgenic, Mesodermal Specific, Dkk1 Mouse Model Recapitulates a Spectrum of Human Congenital Limb Reduction Defects

Overview
Journal Differentiation
Publisher Elsevier
Date 2012 Mar 13
PMID 22406973
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Congenital limb reduction defects occurring in isolation of other developmental abnormalities continue to be an important medical problem in which little progress has been made. Herein we generated transgenic mice expressing Dkk1 in an appendicular mesodermal pattern. Prx1-Dkk1 mice recapitulate a full spectrum of human congenital limb reduction defects, without other developmental issues, and have normal life-spans. Importantly, a close examination of the inheritance pattern suggests that there is a significant degree of incomplete penetrance as progeny of phenotypically positive or phenotypically negative, but genotypically positive Prx1-Dkk1 mice, consistently give rise to both phenotypically positive mice and phenotypically normal-appearing mice. Thus, this heterogeneous phenotype is reproducible with each generation regardless of the phenotype of the parents. We further go on to identify that mesenchymal stem cells from Prx1-Dkk1 mice have limited proliferative ability, but normal differentiation potential, which may explain the mechanism for the limb reduction defects observed. We believe Prx1-Dkk1 mice may prove useful in the future to study the mechanisms underlying the development of congenital limb reduction defects.

Citing Articles

DEC1 deficiency results in accelerated osteopenia through enhanced DKK1 activity and attenuated PI3KCA/Akt/GSK3β signaling.

He S, Guan Y, Wu Y, Zhu L, Yan B, Honda H Metabolism. 2021; 118:154730.

PMID: 33607194 PMC: 8311383. DOI: 10.1016/j.metabol.2021.154730.


Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis.

Luo W, Xu C, Ayello J, Dela Cruz F, Rosenblum J, Lessnick S Oncogene. 2017; 37(6):798-809.

PMID: 29059150 DOI: 10.1038/onc.2017.378.


Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma.

Tannenbaum-Dvir S, Glade Bender J, Church A, Janeway K, Harris M, Mansukhani M Cold Spring Harb Mol Case Stud. 2016; 1(1):a000471.

PMID: 27148571 PMC: 4850889. DOI: 10.1101/mcs.a000471.


Effects of constitutive β-catenin activation on vertebral bone growth and remodeling at different postnatal stages in mice.

Jia M, Chen S, Zhang B, Liang H, Feng J, Zong Z PLoS One. 2013; 8(9):e74093.

PMID: 24066100 PMC: 3774640. DOI: 10.1371/journal.pone.0074093.

References
1.
Boland G, Perkins G, Hall D, Tuan R . Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem. 2004; 93(6):1210-30. DOI: 10.1002/jcb.20284. View

2.
Soshnikova N, Zechner D, Huelsken J, Mishina Y, Behringer R, Taketo M . Genetic interaction between Wnt/beta-catenin and BMP receptor signaling during formation of the AER and the dorsal-ventral axis in the limb. Genes Dev. 2003; 17(16):1963-8. PMC: 196251. DOI: 10.1101/gad.263003. View

3.
Therapontos C, Erskine L, Gardner E, Figg W, Vargesson N . Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci U S A. 2009; 106(21):8573-8. PMC: 2688998. DOI: 10.1073/pnas.0901505106. View

4.
Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos M . Thalidomide in cancer medicine. Ann Oncol. 2004; 15(8):1151-60. DOI: 10.1093/annonc/mdh300. View

5.
Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg S . Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009; 114(2):371-9. PMC: 2714212. DOI: 10.1182/blood-2008-11-191577. View